Compare Alcon AG (ALC) vs Brunswick Corporation (BC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Brunswick Corporation — how do they compare? Alcon AG trades at $75 (market cap $35.19B), while Brunswick Corporation trades at $81.32 (market cap $5.21B). The key difference: Alcon AG is far larger — about 6.8× Brunswick Corporation's market cap, and Brunswick Corporation pays the higher dividend (2.19%). Which is the better fit depends on your goals.
| ALC | BC | |
|---|---|---|
Market Cap | $35.19B | $5.21B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.12 | $89.22 |
52-Week Low | $62.02 | $56.70 |
Enterprise Value | $39.03B | $7.21B |
Dividend Yield | 0.49% | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
BC trades at $81.55, up 0.37% with a bullish technical signal. Recent Q2 2026 earnings beat estimates with EPS of $1.56 versus $1.19 expected. The company maintains a dividend of $0.44 per share and has strong analyst support with 22 buy ratings. However, negative net income margin and ROE highlight profitability challenges amid declining revenue trends from $6.8B in 2022 to $5.4B in 2025.
Outlook is cautiously optimistic due to earnings beats and institutional buying, but high P/E of 73.92 and persistent net losses pose valuation and execution risks. The consensus price target of $85.33 suggests modest upside, contingent on reversing profit declines and stabilizing cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →
